Results 211 to 220 of about 45,567 (253)

Transdermal Delivery of Antisense Oligonucleotides

2004
In recent years, antisense oligodeoxynucleotides (ODNs) have emerged as promising biopharmaceutical therapeutics. These agents specifically target genes or gene transcripts involved in pathogenesis. Several clinical trials have demonstrated the therapeutic value and low toxicity of ODNs (1–5).
Rhonda M, Brand, Patrick L, Iversen
openaire   +3 more sources

Delivery systems for antisense oligonucleotides

Pharmacology & Therapeutics, 2000
In vitro, the efficacy of the antisense approach is strongly increased by systems delivering oligodeoxyribonucleotides (ODNs) to cells. Up to now, most of the developed vectors favor ODN entrance by a mechanism based on endocytosis. Such is the case for particulate systems, including liposomes (cationic or non-cationic), cationic polyelectrolytes, and ...
C, Garcia-Chaumont, O, Seksek, J, Grzybowska, E, Borowski, J, Bolard   +4 more
openaire   +2 more sources

Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides

Pharmaceutical Research, 1999
This review critically examines current understanding of the kinetics and biodistribution of antisense oligonucleotides, both at the cellular level and at the level of the intact organism. The pharmacodynamic relationships between biodistribution and the ultimate biological effects of antisense agents are considered.
R L, Juliano, S, Alahari, H, Yoo, R, Kole, M, Cho   +4 more
openaire   +2 more sources

Oral Delivery of Antisense Oligonucleotides in Man

Journal of Pharmaceutical Sciences, 2008
Treatment of systemic disease with phosphorothioate antisense oligonucleotides (PS ASOs) has been accomplished using local or parenteral routes of administration to date. This report describes, for the first time, the effective oral delivery of a second generation oligonucleotide where significant milligram amounts of intact drug are absorbed in human ...
Lloyd G, Tillman, Richard S, Geary, Gregory E, Hardee   +2 more
openaire   +2 more sources

Nanoparticulate systems for the delivery of antisense oligonucleotides

Advanced Drug Delivery Reviews, 2001
Antisense oligonucleotides are molecules that are able to inhibit gene expression being therefore potentially active for the treatment of viral infections or cancer. However, because of their poor stability in biological medium and their weak intracellular penetration, colloidal drugs carriers such as nanoparticles were developed for the delivery of ...
G, Lambert, E, Fattal, P, Couvreur
openaire   +2 more sources

Delivery of antisense oligonucleotides to PC12 cells

Neuroscience Research, 2002
Optimal experimental conditions for the delivery of phosphodiester or phosphorothioate antisense oligonucleotides (P-ASO/S-ASO) to PC12 cells were determined. Fluorescently labeled P-ASO or S-ASO were transfected to PC12 cells and the uptake of antisense, free or entrapped in liposomes, was monitored by confocal and fluorescent microscopy.
Rosalinda, Acosta, Cecilia, Montañez, Pablo, Gómez, Bulmaro, Cisneros   +3 more
openaire   +2 more sources

Delivery of Antisense Oligonucleotides to the Vascular Wall

2003
Antisense oligonucleotides are short segments of synthetic DNA designed to contain sequences of bases complementary to the DNA or RNA of a particular target gene of interest. By binding to the target, the antisense oligonucleotides can prevent translation of the gene into protein via different mechanisms including destruction of the AS-ODN-nucleic acid
Holt, Cathy M, Gunn, Julian, Lambert, Darren, Cumberland, David C, Crossman, David C   +4 more
openaire   +3 more sources

Delivery of antisense oligonucleotides to neuroblastoma cells

NeuroReport, 2000
pH-Sensitive liposomes composed of dioleoylphosphatidylethanolamine and cholesterol hemisuccinate (3:2 mol/mol) were applied in delivery of antisense oligodeoxynucleotides (asODN) into NG 108-15 neuroblastoma and glioma cells. Fluorescently labelled asODN were entrapped in liposomes by a modified freeze-thawing method (20% encapsulation efficiency ...
N, Skalko-Basnet, M, Tohda, H, Watanabe
openaire   +2 more sources

Delivery of Antisense Oligonucleotide to the Cornea by Iontophoresis

Antisense and Nucleic Acid Drug Development, 2003
We wished to evaluate the potential of iontophoresis to promote the delivery of antisense oligonucleotides (ODN) directed at the vascular endothelial growth factor (VEGF)-R2 receptor (KDR/Flk) to the cornea of the rat eye. Fluorescence (CY5)-labeled ODNs in phosphate-buffered saline (PBS) (20 microM) were locally administered to rat eyes, and their ...
Berdugo, M, Valamanesh, F, Andrieu, C, Klein, C, Benezra, D, Courtois, Y, Behar-Cohen, F   +6 more
openaire   +2 more sources

Targeted delivery of antisense oligonucleotides in cancer

Journal of Controlled Release, 2001
Formulations of antisense oligonucleotides (asODNs) against c-myb or c-myc protooncogenes have been prepared by a new technique that sequesters cationic lipid in the interior of a lipid particle. This technique results in high loading efficiency for the asODNs, small particle size and good stability.
F, Pastorino, D, Stuart, M, Ponzoni, T M, Allen   +3 more
openaire   +2 more sources